Dong X, Zhao X, Xiao T, Tian H, Yun C
Department of Thoracic Surgery, Second Hospital of Shandong University, Jinan, China.
Thorac Cardiovasc Surg. 2011 Apr;59(3):133-6. doi: 10.1055/s-0030-1250152. Epub 2011 Apr 8.
The aim of this study was to investigate the effects of Endostar, a recombined humanized endostatin, on lymphatic tumor growth, lymphangiogenesis and lymphatic metastasis of Lewis lung carcinoma (LLC) xenograft in mice.
Lewis lung carcinoma xenografts were established in C57BL/6 mice by intravenous injection of 1 × 10(6) cells. Then the mice were assigned to two groups: the control group received caudal vein injections of 0.2 ml of 0.9% sodium chloride for 15 days, and the treatment group received 500 µg Endostar daily. Six weeks after LLC cell injection, the mice were sacrificed, and tumor multiplicity and tumor sizes were recorded. The expression of vascular endothelial growth factor C (VEGF-C) and podoplanin were observed by immunohistochemical staining.
Tumor numbers and sizes in the control group were significantly higher than those of the treatment group. The microlymphatic vessel density (MLVD) was 5.67 ± 1.57 in the treatment group, which was markedly lower than in the control mice (7.78 ± 1.56). Two lymph node metastases were observed in the treatment group, and eight in the control group. Lymphatic metastases were more frequent in the control group than in the treatment group. Expression of VEGF-C in the control group was significantly higher than that in the treatment group.
Endostar significantly inhibits the lymphatic tumor growth, lymphangiogenesis and lymphatic metastasis of Lewis lung carcinoma xenografts, and its inhibitory effect is due to its ability to partially regulate the tumor expression of VEGF-C.
本研究旨在探讨重组人源化内皮抑素恩度对小鼠Lewis肺癌（LLC）移植瘤淋巴管生成、肿瘤生长及淋巴转移的影响。
通过静脉注射1×10(6)个细胞，在C57BL/6小鼠体内建立Lewis肺癌移植瘤模型。然后将小鼠分为两组：对照组尾静脉注射0.2 ml 0.9%氯化钠溶液，共15天；治疗组每天注射500 μg恩度。LLC细胞注射6周后，处死小鼠，记录肿瘤数量和大小。采用免疫组化染色观察血管内皮生长因子C（VEGF-C）和血小板内皮细胞黏附分子-1（Podoplanin）的表达。
对照组肿瘤数量和大小显著高于治疗组。治疗组微淋巴管密度（MLVD）为5.67±1.57，明显低于对照组（7.78±1.56）。治疗组观察到2例淋巴结转移，对照组为8例。对照组淋巴转移比治疗组更频繁。对照组VEGF-C表达明显高于治疗组。
恩度显著抑制Lewis肺癌移植瘤的淋巴管生成、肿瘤生长及淋巴转移，其抑制作用可能与其部分调节肿瘤VEGF-C表达的能力有关。
